Synaptogenix (SNPX) Stock Price, News & Analysis

Company Overview

Synaptogenix is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of small‐molecule therapeutics aimed at preserving or restoring synaptic function in neurodegenerative diseases. Its research focuses on addressing the cognitive impairment associated with conditions such as Alzheimer’s disease by targeting pathways critical to neuronal communication and synaptic health.

The company’s lead candidate is in early‐phase clinical studies to assess safety, tolerability and potential efficacy in improving cognitive deficits. Leveraging a proprietary drug discovery platform, Synaptogenix has built a pipeline of novel compounds designed to modulate key synaptic processes and slow disease progression. Research collaborations with academic institutions and neuroscience centers support its preclinical and clinical development efforts.

Based in the United States, Synaptogenix operates laboratories and research facilities focused exclusively on neuroscience drug discovery. The management team brings together professionals with extensive experience in biotechnology and neurodegenerative disease research, guiding the company’s mission to develop innovative treatments for patients suffering from cognitive disorders.

Key Stats

• Today's Range: $6.88 to $7.90
• 50-Day Range: $5.47 to $9.60
• 52-Week Range: $1.84 to $7.85
• Volume: 392,964 shs
• Average Volume: 250,819 shs
• Market Capitalization: $10.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed this year?

Synaptogenix's stock was trading at $3.47 on January 1st, 2025. Since then, SNPX shares have increased by 108.4% and is now trading at $7.23.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:SNPX) issued its quarterly earnings results on Thursday, May, 15th. The company reported $0.04 EPS for the quarter.

When did Synaptogenix's stock split?

Synaptogenix's stock reverse split on Friday, April 5th 2024.The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synaptogenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 10/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.synaptogen.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.28%
• Return on Assets: -58.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 72.59
• Quick Ratio: 72.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,352,000
• Market Cap: $10.05 million
• Optionable: Not Optionable
• Beta: 1.08